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Abstract: Statins are effective in reducing cardiovascular events and are safe for almost all 
patients. Nevertheless, intolerance to statins is frequently faced in clinical practice. This is 
mostly due to muscular symptoms (myalgia with or without increase of plasma creatinine 
kinase) and/or elevation of hepatic aminotransferases, which overall constitutes approximately 
two-thirds of reported adverse events during statin therapy. These side effects raise concerns in 
patients as well as in doctors and are likely to reduce patients’ adherence and, as a consequence, 
the cardiovascular benefit. Therefore, it is mandatory that clinicians improve their knowledge on 
the clinical aspects of muscular and hepatic side effects of statin therapy as well as their ability 
to manage patients with statin intolerance. Besides briefly examining the clinical aspects and 
the mechanisms that are proposed to be responsible for the most common statin-associated side 
effects, the main purpose of this article is to review the available approaches to manage statin-
intolerant patients. The first step is to determine whether the adverse events are indeed related 
to statin therapy. If so, lowering the dosage or changing statin, alternate dosing options, or the 
use of nonstatin compounds may be practical strategies. The cholesterol-lowering potency as 
well as the usefulness of these different approaches in treating statin-intolerant patients will 
be examined based on currently available data. However, the cardiovascular benefit of these 
strategies has not been well established, so their use has to be guided by a careful clinical 
assessment of each patient.
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Introduction
The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, or 
statins, are the mainstay of lipid-lowering therapy because of their well-established 
efficacy for reducing cardiovascular disease (CVD) morbidity and mortality in various 
at-risk populations.1 In general, statin therapy is associated with rare occurrences 
of serious adverse events and is considered to be safe.2,3 Nevertheless, a significant 
proportion of subjects taking these drugs may experience some degree of intolerance. 
In particular, statin-induced myopathy (SIM) is by far the most common side effect. 
A less common side effect of statin therapy is the increase of serum aminotransferase 
levels, which is considered the manifestation of hepatic toxicity.4
Despite the fact that these adverse effects are reversed after treatment withdrawal, 
many patients with an indication for statins refuse therapy because of concerns 
about muscle or liver toxicity. This may represent a significant barrier to maximizing 
cardiovascular risk reduction for many patients with dyslipidemia. Therefore, a better 
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clinician’s ability to manage patients with these problems. 
In this review, after briefly recapitulating incidence data and 
mechanisms whereby statins may cause muscle-related or 
hepatic toxicity, we will examine management strategies for 
patients who are intolerant to statins due to these common 
adverse effects.
Clinical aspects and mechanisms  
of statin-associated adverse effects
Several studies have evaluated the incidence of adverse 
events during statin therapy. In a meta-analysis of over 
70,000 subjects in 18 primary and secondary prevention 
placebo-controlled trials, the number needed to harm 
(NNH) for any adverse event with statins was 197 versus 
27, which was the number needed to treat (NNT) to prevent 
one cardiovascular event.5 In other words, treating 1,000 
patients would prevent 37 cardiovascular events and cause 
5 adverse events. In this analysis, serious adverse events, 
such as creatine kinase (CK) . 10 times upper limit of 
normal (ULN) or rhabdomyolysis, are rare and have a NNH 
of 3,400.   Rhabdomyolysis alone was extremely rare with an 
NNH of 7,428. In the search for differences between statins, 
this study showed that fluvastatin, the least efficacious, had 
the lowest rate of adverse events, and atorvastatin, the most 
efficacious, had the highest rate. Simvastatin, pravastatin, 
lovastatin, and rosuvastatin appeared to have similar rates of 
adverse events. In a systematic review of 20 clinical   trials, 
Law and Rudnicka6 reported that the incidence of myopathy 
and minor muscle pain incidence was 195 cases per 100,000 
patient-years (95% confidence intervals [CI]: -38 to 410). 
The incidence of rhabdomyolysis was 1.6 cases per 100,000 
patient-years (95% CI: -2.4 to 5.5). However, it must be 
noted that the frequency with which clinicians encounter 
SIM in real-world clinical practice is often much higher than 
that reported in clinical trials. One likely explanation for this 
discrepancy is that the rate of myopathy in clinical trials is 
artificially underestimated because patients at increased risk 
for statin-induced adverse effects tend to be excluded prior 
to randomization.7 Also, many patients in clinical practices 
may not be as healthy as those enrolled in clinical trials and 
often have more severe comorbidities.
Data on the real-world incidence of SIM may be avail-
able through several drug side-effect reporting systems. 
For example, in the Food and Drug Administration’s (FDA) 
Adverse Event Reporting System database recorded until 
2002, the reporting rates per million statin prescriptions was 
0.38 cases for myopathy and 1.07 cases of rhabdomyolysis.8 
However, this source might produce biased information due 
to the fact that the event reporting is voluntary and thus may 
have resulted in underreporting of adverse effects. To obtain 
data that are representative of the clinical practice, it may be 
helpful to examine databases from cohort studies or from 
closed systems such as managed care   organizations. The 
Prediction of Muscular Risk in Observational Conditions 
(PRIMO) produced one of these databases.9 In the PRIMO 
study, over 7,900 hyperlipidemic patients treated with high-
dose statin therapy were enrolled in a 12-month, prospective 
observational follow-up. Muscle symptoms were reported by 
11% of patients. This figure has been confirmed by others,10 
so we can reasonably state that SIM may affect 10%–15% 
of statin users.
The clinical presentation of statin myopathy varies from 
mild fatigue to rhabdomyolysis requiring hospitalization. The 
most frequently reported symptoms include myalgia, fatigue, 
weakness, generalized aching, and low back or proximal 
muscle pain.2,11,12 There have been less frequent complaints 
of tendon pain and nocturnal muscle cramps.11 According 
to well accepted definitions, myalgia is defined as muscular 
symptoms without CK elevations; myositis refers to muscle 
symptoms with CK elevation; and rhabdomyolysis is defined 
as muscle symptoms with marked CK elevations (.10 times 
ULN) with an elevated plasma creatinine and the occasional 
presence of brown urine.12
The temporal relationship between initiation of statin 
treatment and onset of symptoms is widely variable, as is the 
time between cessation of statin treatment and the resolution 
of symptoms. In a study that used two large UK primary care 
databases covering an active population of about 5 million 
people and including many patients with a follow-up period 
of over ten years, it has been reported that most SIM cases 
occur within the first 12 weeks of statin exposure, but few can 
be seen up to 52 weeks of treatment.13 SIM does not appear 
to be related to statin dosage. In a review of several atorvas-
tatin trials, treatment-related myalgia occurred at a similar 
rate of 1.4% and 1.5% in subjects receiving 10 or 80 mg of 
atorvastatin compared with a rate of 0.7% with placebo.14 
A retrospective analysis of safety from the PROVE-IT trial 
also suggested that statin adverse effects are not related to 
low density lipoprotein (LDL) level.15 In fact, muscular and 
hepatic side effects were found to occur at the same rate 
across all on-treatment LDL-cholesterol (LDL-C) levels, 
including very low levels of 40 mg/dL. This phenomenon 
has been confirmed in a recent meta-analysis comparing 
different statin doses and on-treatment LDL-C levels.16 
Although the exact mechanisms causing SIM has not been 
determined, several hypotheses have been proposed. It has Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
157
Statin-intolerant patients
been suggested that cholesterol reduction with statins may 
perturb the   integrity of the plasma membrane of myocytes 
because cholesterol plays a key role in cell membrane 
  fluidity.17   Others have proposed that statins induce myopa-
thy by favoring the deficiency of coenzyme Q10 (CoQ10), 
which is a metabolite of the HMG-CoA reductase pathway.18 
CoQ10 plays a key role in the electron transport chain, and 
a reduction in this coenzyme could result in an abnormal 
mitochondrial respiratory function. However, several lines 
of evidence make these explanations unlikely. Firstly, when 
cholesterol is decreased by inhibiting squalene synthetase, 
no increase in myotoxicity is observed.19 Human and animal 
studies have demonstrated that statin treatment may reduce 
serum CoQ10 levels; however, myocyte CoQ10 levels have 
not been consistently decreased with statin treatment.20
Another possible explanation of SIM relates to the obser-
vation that statins induce the apoptosis or programmed cell 
death of myocytes by reducing isoprenoids levels. Isoprenoids 
are lipids produced by HMG-CoA reductase pathway.21 
Isoprenoids are linked to proteins by a process known as 
farnesylation. According to this theory, statins block the 
production of farnesyl pyrophosphate and this prevents the 
prenylation of GTP-binding proteins Ras, Rac, and Rho. 
A reduction in the levels of the prenylated forms of these 
proteins leads to increased cytosolic calcium levels with 
subsequent activation of the proteolytic enzymes capsase-3 
and capsase-9, which have a central role in cell death. This 
theory is also supported by an in vitro study demonstrating 
that statin-induced apoptosis of muscle cells is prevented by 
supplementation with the isoprenoids farnesyl pyrophosphate 
and geranylgeranyl pyrophosphate but not CoQ10.22 Finally 
it has been proposed that statins impair intracellular calcium 
homeostasis by interfering with the mitochondrial respiratory 
chain and by affecting ryanodine receptor one (RyR1), which 
pumps calcium into the cytoplasm. Increased cytoplasmic 
calcium levels have been shown to cause cramps, myalgias, 
and apoptosis.23,24
Recently, genetic risk factors for statin myopathy have 
been identified. Investigators from the ongoing Study of the 
Effectiveness of Additional Reductions in Cholesterol and 
Homocysteine (SEARCH) trial hypothesized that strong 
associations might exist between treatment with a high-dose 
statin regimen and genetic variants that affect statin blood 
levels.25 In this trial, a genome-wide analysis demonstrated 
that myopathy was strongly associated with a single nucle-
otide polymorphism within intron 11 of SLCO1B1 on 
  chromosome 12. SLCO1B1 is the gene that encodes the 
organic anion transporting polypeptide responsible for 
hepatic uptake of statins. In the SEARCH, 60% of the cases 
of myopathy were associated with SLCO1B1 variants.
The most commonly encountered hepatic biochemical 
abnormality during statin therapy is the asymptomatic 
elevation of aspartate aminotransferase (AST) and alanine 
aminotransferase (ALT) which appears to be a class effect 
of statins.2,4 This has been also defined as ‘transaminitis’, 
in which liver enzymes are elevated in the absence of clear 
  hepatoxicity. This condition is usually transient with full 
resolution following withdrawal of the drug, although this 
may take several months. It is rare for statins to cause isolated 
elevations in gamma-glutamyl transferase (GGT).26 Several 
reports indicate that the occurrence of aminotransferase 
elevation during statin therapy ranges from 1%–3%.27,28 
This effect appears to be dose related29,30 and hence may be 
related to bioavailability. In a recent meta-analysis,16 it has 
been shown that atorvastatin 80 mg and simvastatin 80 mg are 
associated with a persistent elevation of ALT (.3 times ULN) 
up to 5 times compared to atoravastatin 10 mg and simvastatin 
20–40 mg (0.2% vs 1.0%).   Hepatocellular injury seen during 
statin therapy seems to be an early side effect as demon-
strated in several statins trials where AST and ALT elevation 
appeared in the initial 3 months of treatment.31 Liver-related 
symptoms occurred on average 4 weeks (range 1 to 8 weeks) 
after initiation of treatment but resolved within 4 weeks of 
statin therapy discontinuation.
The mechanism by which statins may induce hepatocel-
lular injury is unclear. Animal studies have suggested that the 
depletion of mevalonate or one of its sterol metabolites caused 
by the inhibition of 3-hydroxyl, 3-methyl-glutaryl-CoA 
reductase (HMG-CoA) enzyme may be responsible for 
the elevated liver enzymes.32 It has been suggested that the 
inherent metabolic characteristics of statins may have some 
relevance. In fact, the different statins have distinctly different 
metabolic pathways, as simvastatin, lovastatin, fluvastatin, 
and atorvastatin are metabolized by cytochrome P450 system, 
whereas pravastatin, rosuvastatin, and pitavastatin undergo 
minimal hepatic metabolism. Moreover, statins vary in 
their degree of lipophilicity, which may have an impact on 
their likelihood of being associated with aminotransferase 
  elevations. The meta-analysis by Dale et al33 demonstrated 
that the less lipophilic statins (pravastatin, rosuvastatin, 
atorvastatin, fluvastatin) increased the relative risk of ami-
notransferase elevation compared to the more lipophilic 
ones (lovastatin, simvastatin, cerivastatin). In this regard, it 
is interesting to note that the opposite has been observed for 
CK elevation.12,13 A clear explanation for this is not avail-
able even though one could implicate the hepatic organic Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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anion transport protein (OATP or SLCO1B1) that plays an 
important role in facilitating the penetration of statin into the 
hepatocytes. It has been reported that genetic variations in 
SLCO1B1 have a larger effect on the area under the plasma 
concentration-time curve of atorvastatin than that observed 
with the more hydrophilic rosuvastatin.34
The natural history of elevated liver enzymes due to the 
long-term use of statins is poorly understood. However, it is 
recognized that in some individuals, this elevation is transient 
and may be physiological rather than pathological and that 
some patients display ‘adaptation’, where liver enzymes sta-
bilize/normalize if the drug is not withdrawn.35 There are no 
studies that correlate hepatic histology with elevations in liver 
enzymes to differentiate between true hepatotoxicity and an 
adaptive process. The US National Lipid Association’s (NLA) 
Safety Assessment Task Force concluded in 2006 that there 
was no evidence of a relationship between elevated transami-
nases, statin therapy, and risk of significant liver injury.4 
Furthermore, they also concluded that routine monitoring 
of liver enzymes did not identify those individuals at risk 
of developing idiosyncratic liver failure. In addition, recent 
evidence suggests that moderate elevation of transaminases 
should not contraindicate the initiation of statin therapy. 
A post-hoc analysis of the secondary prevention Greek Ator-
vastatin and Coronary Heart Disease Evaluation (GREACE) 
study,36 assessed the cardiovascular and liver outcomes in 
a total of 437 patients presenting moderately elevated liver 
enzymes (,3 times ULN) at enrollment, possibly associated 
with non-alcoholic fatty liver disease. Two hundred twenty-
seven of these individuals who were treated with a statin 
(mainly atorvastatin, 24 mg per day) had substantial improve-
ment in liver tests (P , 0.0001), whereas the 210 individuals 
not treated with a statin had further increases of liver enzyme 
concentrations during the 3-year follow-up of this study. 
Furthermore, patients with abnormal liver tests who received a 
statin experienced fewer cardiovascular events in comparison 
to patients with abnormal liver tests who did not receive one 
(68% relative risk reduction, P , 0.0001). Interestingly, this 
cardiovascular benefit was greater (P = 0.0074) than it was 
in patients with normal liver enzymes.
The most frequently seen histological appearance of 
statin-induced liver injury is inflammation of the portal tracts 
with mild piecemeal necrosis and focal periportal fibrosis.37 
As serious hepatotoxicity caused by statins is rare, these find-
ings are seldom seen. The FDA’s Adverse Event Reporting 
System database until 2004, reported a rate of 0.69 cases of 
liver failure/hepatitis per million statin prescriptions, a figure 
similar to that reported for liver failure/hepatitis in the general 
adult population.4 Analysis of an administrative database 
showed 6.1 to 12.8 hepatic events per 10,000 person-years 
of hospitalized patients on statins.38 None were hospitalized 
within 6 months of starting their statin. Furthermore, only 1 
of the 51.741 patients who underwent liver transplantation 
between 1990 and 2002 was taking a marketed statin.27,39
However, recent literature indicates that potential remains 
for these more serious hepatotoxic reactions in association 
with statins. Adverse drug reaction reports from the UK 
Committee on Safety of Medicines show four deaths caused 
by atorvastatin-induced hepatotoxicity over an eight-year 
period (0.5 deaths per annum).40 In addition, there are also 
reports of rosuvastatin, fluvastatin, and atorvastatin induc-
ing or revealing autoimmune disease, including autoim-
mune hepatitis. This is an extremely rare effect and there is 
evidence that the hepatic effect may be reversible when the 
drug is withdrawn.41–43 Finally, in very rare circumstances, 
statin therapy may cause liver failure.44 Overall, the long-term 
hepatic safety of statins is reassuring. It has been, in fact, 
reported that 24 million years of patient treatment with lovas-
tatin reveal a rate of acute liver failure of 1 per 1.14 million 
patient-treatment years, which is similar to the rate of idio-
pathic acute liver failure.37 Nevertheless, the potential for 
statin-associated severe liver injury makes the monitoring of 
liver enzymes during this treatment important to recognize 
drug-induced liver injury as early as possible.
Strategies for managing statin 
intolerant patients
The first step in the management of intolerance to statins 
is to rule out any possible conditions that increase the risk 
of developing SIM or aminotransferase elevations. A list of 
the most common of these conditions is reported in Table 1. 
The National Lipid Association Statin Safety Task Force has 
provided recommendations for the management of muscle-
related symptoms in patients receiving statin therapy4 and 
these are incorporated in Figure 1. In summary, in patients 
with moderate symptoms and without significant CK eleva-
tion (, 5 × ULN), progress can be followed clinically. On 
the other hand, in patients with severe symptoms and in those 
with CK elevated more than 5 × ULN, statins should be 
stopped. Once CK is normalized, patients should be rechal-
lenged with the same statin at the same dosage. Otherwise, 
different approaches can be considered (Table 2). The use of 
agents (coenzyme Q10 and vitamin D preparation) to allevi-
ate muscular symptoms has also been proposed.
Guidelines have also been issued to manage liver intolerance 
to statins,4,26,27 and these are summarized in   Figure 2. Baseline Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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Table 1 Potential risk factors for statin-induced myopathy (SiM) 
and hepatic side effects of statins
Statin-induced myopathy Hepatic toxicity
Frailty and low body mass index Acute viral diseases
Advanced age (.80 y) Alcohol-associated liver diseases
High physical activity Advanced chronic liver diseases
Heavy alcohol consumption Mildly lipophilic statins
Drugs affecting statin metabolism 
(gemfibrozil, cyclosporin, amiodarone, 
macrolides antibiotics, verapamil, 
systemic use of azole antifungale, 
warfarin, protease inhibitors)
Genetic factors (CYP450 
isoenzymes)
Renal insufficiency
Hypothyroidism
Rheumatic diseases
Metabolic muscle diseases
Major surgery
Genetic factors (CYP450 variants,  
drug transporter variants)
Determine CK and rule out
other causes of myopathy
Myalgia
Tolerable muscle pains
and no or mild CK
elevation <5 × ULN
Continue statin at the
same or reduced dosage,
use symptoms as a guide
Tolerable muscle 
pains but
CK >5 × ULN
Intolerable muscle pains
also without significant
CK elevation
Rhabdomyolisis
Carefully reconsider risk 
benefit of statin therapy
Discontinue statin therapy; once symptoms
disappear, restart with the same statins at 
lower dosage or use a different statin
If symptoms recur consider:
If symptoms recur with multiple statins at multiple doses
start:
If unable to tolerate nonstatin drugs
– combination therapy (ezetimibe) with lower statin dosage
– rosuvastatin at low dosage (2.5–5 mg)
– rosuvastatin (5–10 mg) or atorvastatin (10–20 mg) at
alternate-day or weekly dosing
– Nonstatin drugs (BSA fibrates, nicotinic acids and ezetimible 
alone or in combinations)
– red yeast (at monacolion K content dose range from 5–10 mg)
– plant sterols or combination
Figure 1 Algorithm for management of statin induced myopathy.
Abbreviations: BSA, bile acid sequestrants; CK, creatine kinase; ULN, upper limit of normal.
elevations of hepatic transaminases ,3 times ULN are not a 
contraindication to statin therapy. Many patients with diabe-
tes, metabolic syndrome, or obesity have nonalcoholic fatty 
liver disease with transaminase levels fluctuating between 
1.5 and 3 × ULN.29 After establishing that no other etiologies 
are responsible for the transaminase elevations, a statin at a 
low-to-moderate dose can be started while monitoring alanine 
aminotransferase levels. No consensus exists regarding the 
best time to recheck liver biochemistry values. In the HPS 
and in the AFCAPS/TexCAPS trial, the liver profile was 
rechecked after 3 and 2 weeks, respectively, with normal-
ization of the values in more than 70% of the cases. Other 
authors suggest repeating the test after 6 weeks.45 In cases 
where the increment in aminotransferase levels is .3 × ULN, 
it is recommended to stop the treatment and reassess liver 
tests. After that, rechallenging the patient with the same drug 
and dose, a different statin, or the same statin at a lower dose 
should be attempted.26,27 The ideal time period between the 
normalization of the liver enzyme levels and the initiation 
of the rechallenge is not well-specified. Conversely, when 
the elevation in aminotransferase levels is persistent after 
statin withdrawal or reoccurs after a statin rechallenge, 
other options should be considered. Several authors have 
recommended using low-dose statin treatment because of 
the possible greater incidence of liver enzyme elevations with 
higher doses. It has also been proposed that liver biochemistry 
monitoring should be performed every month for the first 3 
to 4 months and four times a year thereafter. Additionally, the 
use of statins, which are not metabolized by the liver or the Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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use of nonstatin compounds can be considered. A detailed 
evaluation of the different options to manage statin intolerant 
patients is reported below.
Switching to another statin
Data demonstrating the usefulness of switching intolerant 
patients to another statin are scarce. Hansen et al,46 in a 
follow-up of 45 patients with confirmed SIM, found that 37 
of them received another statin. Twenty-one patients (57%) 
reported recurrent muscle pain, whereas 16 (43%) tolerated 
the new statin without reporting symptoms. These data dem-
onstrate that the recurrence of symptoms is very common on 
rechallenge and indicate that this strategy may be useful in 
only some patients. The criteria to select the new statin are 
not well-defined. One possibility could be to change from a 
Increased
aminotransferases
<3 × ULN >3 × ULN
Continue statin and
recheck liver 
enzyme within 6 weeks
Withhold statin therapy
and reassess liver 
enzymes
Normal
Low suspicion of
statin related
hepatic injury
causes corrected
Consider other causes
of liver damage 
(alcohol, hepatitis,
drug interaction)
Rechallenge the same
statin at lower dosage
or other statin with
different metabolism,
consider other options
as in table 2
Persistently elevated
Figure  2  Algorithm  for  management  for  abnormal  liver  enzymes  during  statin 
therapy.
Abbreviation: ULN, upper limit of normal.
Table 2 Possible approaches to manage statin intolerant patients
• Switching to another statin (preferably with different metabolism)
• An alternate-day or weekly dosage of statins with longer half-life
• Combination therapy (with ezetimibe) with infrequent statin dosing
• Nonstatin lipid lowering drugs (BSA ezetimibe, fibrate, nicotinic acid)
• Dietary manipulation and nutraceuticals
Abbreviation: BSA, bile acid sequestants.
mildly to a highly lipophilic statin or from a P450-dependent 
to a non-P450-dependent statin.
Another option may be to switch to a lower dosage of a 
more potent statin. Glueck et al47 designed a study to evaluate 
the effectiveness and safety profile of rosuvastatin at doses 
of 5 and 10 mg/day in consecutively referred patients with 
primary high LDL-C who were unable to tolerate other sta-
tins because of myalgia. This was a prospective, open-label 
pilot study enrolling 61 male and female patients aged 38 to 
80 years with primary high LDL-C (mean 177 mg/dL). After 
prescribing diet, rosuvastatin 5 mg/day was administered to 
patients categorized by the National Cholesterol Education 
Program Adult Treatment Panel (NCEP ATP III) risk strati-
fication as moderately high risk, and rosuvastatin 10 mg/day 
was administered to patients categorized as high or very high 
risk. After treatment of over 36 weeks, rosuvastatin 5 and 
10 mg were associated with a LDL-C reduction of 42% and 
39%, respectively (P , 0.001 vs baseline). Of the 61 patients, 
one receiving the 10-mg dose discontinued rosuvastatin treat-
ment because of unilateral muscular pain after 4 weeks; no 
significant aminotransferase or CK elevation was seen.
Alternate-day statin dosing
Several studies have evaluated non-approved statin dosing 
regimens in patients with SIM. Some have tested rapidly 
metabolized statins, such as lovastatin48,49 fluvastatin,50 or 
simvastatin.51 However, this approach has been based on 
the concept that statins with a longer half-life may maintain 
their lipid lowering effect over a longer period of time. For 
example, atorvastatin has a mean terminal half-life of 14 h 
and generates two active (orthohydroxy and parahydroxy) 
metabolites.52 These metabolites contribute to 70% of its 
HMG-CoA reductase activity and have a half-life of 20–30 h.53 
This justifies the use of atorvastatin in alternate-day dosage as 
it maintains its cholesterol lowering efficacy for longer.
Two studies have evaluated the potentiality of this 
approach in noncontrolled trials. In the first study,54 
61 patients with hypercholesterolemia received atorvastatin 
(10 mg) every other day before bedtime. After 8 weeks of 
treatment, total cholesterol and LDL-C were lowered by 23% 
and 30%, respectively, and total triglycerides were reduced 
by 8%; the increase in high density lipoprotein-cholesterol 
(HDL-C) level was not statistically significant. For the   second 
study,55 25 patients with moderate hypercholesterolemia 
were treated with every-other-day administration of either 
atorvastatin (mean dose, 18.8 mg) or rosuvastatin (mean dose, 
9.7 mg). With atorvastatin LDL-C decreased by 43%, total 
triglycerides by 22%, and HDL-C cholesterol increased by Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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9% (n = 9; P , 0.05 for all), while with rosuvastatin, LDL-C 
decreased by 28%, total triglycerides by 15% and HDL-C 
increased by 10% (n = 16; P , 0.05 for all).
Three other studies employed randomized, controlled 
designs. Matalka et al56 reported the results of the Alternate 
Day versus Daily Dosing of Atorvastatin study (ADDAS). 
This was a comparative efficacy and cost-effectiveness 
study in 35 patients randomly assigned to receive 10 mg of 
  atorvastatin daily or on alternate days. Dosage was adjusted 
to achieve the NCEP ATP III targets. Authors reported a 35% 
reduction in LDL-C with 20 mg every other day (mean dose 
18 mg) compared with 38% reduction with 10 mg every day 
(mean dosage 12 mg/day). This difference was not statisti-
cally significant.
Jafari et al57 investigated 54 patients with LDL-C ranging 
100–200 mg/dL. These patients were randomized into three 
atorvastatin dose groups: 10 mg every day, 10 mg every 
other day, and 20 mg every other day. After 6 weeks of 
treatment, all three regimens significantly reduced total 
and LDL-C compared to baseline and more importantly, 
no statistically significant differences existed between the 
three groups. All regimens were well tolerated and none of 
the patients had a significant elevation of liver enzymes or 
CK during the course of the study. In a more recent study,58 
61 patients with LDL-C levels above 130 mg/dL were ran-
domized to receive 20 mg atorvastatin every day or every 
other day. In the every-other-day treatment group, there was 
a 36.1% reduction in LDL-cholesterol levels by the end of 
the first month (P , 0.01). At the end of 3 months there was 
a further decrease of 10.2% in LDL-cholesterol levels when 
compared to the 1 month levels (P . 0.05). The LDL-C 
levels of the group receiving 20 mg atorvastatin every day 
was reduced by 41% by the end of 1 month (P , 0.01). At 
the end of 3 months, the difference between the changes in 
the all lipid parameters of the two groups was not found to 
be of statistical significance. Interestingly, both regimens 
significantly decreased high sensitivity-CRP and this effect 
was not different between the two treatment arms.
Ferrer-Garcia et al59 considered the alternate-day 
approach in patients with type 2 diabetes mellitus. They 
enrolled 41 patients that were assigned to receive 10 mg 
atorvastatin as an initial dose every day until they reached the 
ATP III recommended LDL-C target (,100 mg/dL). After 
achieving LDL , 100 mg/dL, the patients were assigned 
to the   corresponding atorvastatin dose every other day for 
12 weeks. Thirty-three patients correctly completed the study. 
LDL-C decreased 39% after the everyday period and 23% 
after the alternate-day atorvastatin dosing period (P , 0.05). 
The target LDL-C concentration of ,100 mg/dL was main-
tained in 19 patients (57.6%) during the alternate-day period. 
None of the 33 patients showed elevations in liver enzymes 
or CK during the alternate-day dosing period.
Rosuvastatin, the other statin that exhibits a long half-
life (19 h), has also been employed in trials testing the 
infrequent statin dosing regimen. Mackie et al60 described 
two patients who were unable to tolerate daily atorvastatin 
therapy secondary to myalgias and were subsequently treated 
with rosuvastatin administered on Mondays, Wednesdays, 
and Fridays, at 2.5 and 5 mg, respectively. After 6 weeks, 
LDL-C was reduced by 38% and 20%, respectively with 
the resolution of adverse effects. In a retrospective analysis 
of clinical charts at two lipid clinics,61 51 patients that had 
experienced statin intolerance were found to be treated with 
every-other-day rosuvastatin (mean dose 5.6 mg). The authors 
reported that 72.5% (37 out of 51) of patients were able to 
tolerate this regimen for 4 months. Mean LDL-C decreased 
by 34.5% (P , 0.001) in patients who tolerated the regimen, 
enabling approximately 50% to achieve their LDL-C goal. 
Among patients treated with the every-other-day regimen, 
27.5% (14 out of 51) re-experienced the symptoms of their 
prior statin intolerance.
In a 8-week, randomized, open-label, parallel trial, 
  Wongwiwatthananukit et al62 evaluated the effect of 10 mg 
rosuvastatin administered once daily or every other day in 
81 patients with primary hypercholesterolemia. Among 
the 76 patients that completed the study, LDL-C levels 
were reduced by 48% and 39% in the once-daily and 
every-other-day groups, respectively (P = 0.011). The per-
centage of patients who achieved LDL-C goals according 
to NCEP ATP III guidelines was not significantly different 
between the once-daily (85%) and every-other-day (70%) 
groups (P = 0.180). In addition, both regimens were well 
tolerated, with no patient developing an elevation of more 
than 3 times baseline levels of aspartate aminotransferase or 
alanine aminotransferase or 10 times that of CK.
Gadarla et al63 also utilized rosuvastatin, at doses of 5 
and 10 mg twice weekly (Monday and Thursday) for a time 
longer than 3 weeks, in patients (mean age 62 ± 8 years) with 
SIM related to other lipid-lowering therapy (other statins or 
niacin or fibrate or combinations of these). This choice was 
well tolerated by 80% of patients and produced a significant 
26% reduction of LDL-C from baseline.
Backes et al64 described eight patients with previous intol-
erance to daily statin dosing and examined their responses 
to once-weekly rosuvastatin therapy (5–20 mg). Overall, 
this small group experienced a mean LDL-C reduction of Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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29%. Possible explanations for tolerance according to the 
once-weekly regimen may include lower overall plasma 
concentrations from the less frequent dosing and the psycho-
logical factor of receiving only a once-weekly dose.
A larger study with similar dosing protocol was carried 
out by Ruisinger et al65 who enrolled 50 patients with a 
previous statin adverse event. Rosuvastatin once per week 
was tolerated by 37 (74%) of the 50 study participants, with 
doses ranging from 2.5 to 20 mg a week (mean 10 mg). 
Patients tolerating the once-a-week regimen experienced a 
17% reduction in total cholesterol, 23% reduction in LDL-C, 
12% reduction in triglycerides, and a 5% increase in high-
density lipoprotein cholesterol (all P , 0.001), during a mean 
follow-up of 4 months.
Although the alternate-day statin dose administration 
has been demonstrated to be feasible and effective, some 
limitations must be stressed. First of all, it must be pointed 
out that this regimen allows a lower LDL-C reduction (up to 
10%–15% less) compared to the every day regimen. This must 
be  carefully considered in light of the ideal LDL-C target for 
each patient. Furthermore, these dosing regimens have not 
been proven to reduce cardiovascular events. Therefore, they 
must be always be regarded as alternative treatment options 
in well-selected patients such as those who did not tolerate 
more than one statin, even at lower dosage, and may otherwise 
go without any benefits from statin therapy.
Combination therapy with infrequent 
statin dosing
Athyros et al66 investigated a novel approach to managing 
  statin intolerant patients based on the use of combination 
therapy where a statin was administered with an alternate 
dosing. They initially started 56 statin-intolerant patients 
on ezetimibe (10 mg/day). After evaluating the patients’ 
responses, they added atorvastatin, 10 mg twice weekly. 
Only 9% of the patients achieved their LDL-C goal on 
  monotherapy, but 84% achieved the NCEP ATP III LDL-C 
target levels with the combination, which lowered LDL-C 
by 34%.
Nonstatin lipid-lowering drugs  
alone or in combination
If myopathy recurs after trials with both multiple statins and 
a variety of dosing regimens, then nonstatin lipid lowering 
agents should be considered. These drugs include a bile acid 
sequestrant (colesevelam), an intestinal cholesterol absorp-
tion inhibitor (ezetimibe), fibrates, and niacin used alone or 
in combination.
Colesevelam is a nonabsorbable engineered polymer 
(water soluble hydrogel), which binds anionic and hydro-
phobic bile acids with higher affinity than cholestyramine. 
Dosage of 2–4 g/day results in a 15%–19% reduction of 
LDL-C.67 Conversely, ezetimibe is a specific inhibitor of 
intestinal cholesterol absorption through blocking the activ-
ity of NPC1L1 transporter and at the dosage of 10 mg/day, 
is able to decrease LDL-C by 15%–20%.68 Colesevelam 
shows a better intestinal tolerability than cholestyramine 
and ezetimibe has no relevant side effects. Based on their 
safety profiles, these drugs may be used as monotherapy 
or in combination in the management of statin-intolerant 
patients. Gazi et al69 reported that among 27 statin-intolerant 
patients who started treatment with ezetimibe monotherapy, 
25 completed three months of therapy showing a reduction 
of total and LDL-cholesterol of 18% and 26%, respectively 
(P , 0.001 for both). In another retrospective review of 
16 statin-intolerant patients with diabetes mellitus or meta-
bolic syndrome, Rivers et al70 reported that the combination 
of ezetimibe (10 mg/day) plus colesevelam (1.875 g twice 
daily) was well tolerated and determined a marked reduc-
tion of both LDL-C (42.2%), and non-HDL-C (37.1%). 
Fibrates have been reported to be very effective in patients 
with atherogenic dyslipidemia (high triglycerides and low 
HDL).71 McKenney et al72 examined the safety and efficacy 
of long-term coadministration of fenofibrate and ezetimibe 
in patients with mixed hyperlipidemia. In this study, the 
baseline total cholesterol was 262 mg/dL, HDL-C 42 mg/dL, 
LDL-C 162 mg/dL, and triglyceride level 276 mg/dL. There 
was a reduction in LDL-C by 20%, non-HDL-C by 30%, 
and apolipoprotein B by 26% on the combination therapy. 
All levels were significantly reduced compared with either 
monotherapy.
Niacin alone or associated with laropiprant has 
been reported to be effective in reducing LDL-C, total 
  triglycerides, and increasing HDL, thus making it a possible 
alterative in patients with dyslipidemia.73 At present no data 
are available in the literature on the use of nicotinic acid in 
statin intolerant patients. Nevertheless, it must be noted that 
randomized controlled trials carried out in the pre-statin era 
clearly demonstrated that niacin was beneficial in preventing 
coronary events.74 Additional studies further demonstrated 
that this drug in combination with bile acid sequestrants was 
also able to slow the progression of coronary lesions.75,76 
Very recently, two meta-analyses reviewed the effects of 
niacin alone or in combination on all cardiovascular events 
and on atherosclerosis in a total sample of about 6500 
patients.77,78 These studies consistently reported that niacin Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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significantly reduced major coronary events by 25%, stroke 
by 26%, and any   cardiovascular events by 27%. Moreover, 
when the effect of niacin on atherosclerosis evolution was 
evaluated,78 it was found that in comparison with the non-
niacin group, more patients in the niacin group experienced 
regression of coronary atherosclerosis (92% relative increase) 
whereas the rate of patients with progression decreased by 
41%. Similar effects of niacin were found on carotid intima-
media thickness with a weighted mean difference in annual 
change of -17 µm/year.
Dietary manipulation and lipid 
lowering nutraceuticals
Strengthening the efficacy of lipid-lowering dietary inter-
ventions may be a reasonable consideration in patients 
who cannot take statins. This may be obtained by com-
bining dietary ingredients showing cholesterol-lowering 
properties such as foods low in saturated fat and high in 
viscous fibers (eg, oats and barley), plant sterols, vegetable 
protein foods (soy), and nuts (eg, almonds). Jenkins et al79 
evaluated the efficacy of this dietary portfolio versus 
lovastatin in 46 hyperlipemic adults. Participants were 
randomly assigned to a diet very low in saturated fat, 
based on whole-wheat cereals and low-fat dairy foods 
  (control); the same diet plus lovastatin, 20 mg/d (statin); 
or a diet high in plant sterols (1.0 g/1000 kcal), soy protein 
(21.4 g/1000 kcal), viscous fibers (9.8 g/1000 kcal), and 
almonds (14 g/1000 kcal) (dietary portfolio). After four 
weeks, changes in LDL-C were 8.0% (P = 0.002), 30.9% 
(P , 0.001), and 28.6% (P , 0.001), in the control, statin, 
and portfolio diets, respectively. It is important to note that 
the dietary portfolio led to a cholesterol reduction that was 
comparable to that observed with statin. Unfortunately, a 
limitation of this dietary formulation is the palatability. In 
fact, only 40% of participants to the Jenkins’s trial found 
the dietary portfolio acceptable while the remaining thought 
that a greater variety of foods was required.
Dietary supplementation with nutraceuticals showing 
lipid-lowering effects may be an alternative option. Among 
these compounds, the yeast rice is of particular interest. 
  Chinese red yeast rice is a dietary supplement made by 
fermenting the yeast, Monascus purpureus, over rice. 
Monascus yeast produces a family of substances called 
monacolins capable of inhibiting the enzyme HMG-CoA 
reductase and also contains unsaturated fatty acids and 
phytosterols.80 Becker et al81 evaluated this supplement to 
control hypercholesterolemia in statin-intolerant patients. 
They randomly assigned 62 patients with dyslipidemia 
(baseline LDL-C 163.3 mg/dL) to receive red yeast rice, 
1800 mg (31 patients), or placebo (31 patients) twice daily 
for 24 weeks. All patients were concomitantly enrolled in 
a therapeutic lifestyle change program. Red yeast rice and 
therapeutic lifestyle change decreased LDL-C level by 
27.3% after 12 weeks and this reduction was maintained 
after 24 weeks of therapy (-21.3%). No increases in CK or 
pain levels were seen. In another study,82 43 patients with 
dyslipidemia and a history of statin discontinuation for 
myalgia were randomly assigned to red yeast rice 2400 mg 
twice daily or pravastatin 20 mg twice daily for 12 weeks. 
The LDL-C level decreased 30% in the red yeast rice group 
and 27% in the pravastatin group. A more recent report83 
describes the results retrospectively observed in 25 patients 
who underwent treatment with red yeast rice for more than 
4 weeks due to intolerance to lipid lowering medications. In 
those unable to tolerate daily statin use, the total cholesterol 
decreased 13% and LDL-C decreased 19% (P , 0.001 
compared to baseline).
One limitation of this therapeutic strategy is related to 
the fact that the LDL-C lowering potency of yeast rice is 
modest (ranging up to 20%) so that its use can be proposed 
only in low-risk individuals or in those whom LDL-C is 
not far from the target. The prescription of combinations 
of different lipid-lowering nutraceuticals may be a way 
to increase the LDL-lowering efficacy of this approach. 
Cicero et al84 assessed the long-term effectiveness of daily 
administration of a combination of 2 g phytostanols, 500 mg 
berberine, and 3 mg monacoline in 48 statin-intolerant 
hypercholesterolemic patients. After 3 months, LDL-C was 
significantly decreased by 31% and total triglycerides by 
16%; more importantly, these effects were maintained up 
to the 1-year follow-up.
Although these results are intriguing, several aspects must 
be considered. The cholesterol-lowering effect of red yeast 
rice is due to monacolin K, a natural form of lovastatin. The 
monacolin K content can vary widely between brands, and 
most patients purchase this supplement without verification 
of the monacolin K content. In addition, monacolins cannot 
be used as a dietary supplement at the dosage employed in 
the reported trials in some countries. Finally, there is no 
direct evidence that the use of nutraceuticals may produce 
any benefits in terms of cardiovascular prevention. Therefore, 
we agree with the concept that these agents should be con-
sidered as a fourth line approach,7 only after patients have 
demonstrated intolerance to multiple statins used at lower-
than-recommended doses, after using infrequent statin dosing 
protocol or after trials with nonstatins drugs.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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Specific treatments of statin-
induced myopathy
There is limited experience concerning specific treatments 
of SIM. As it has been reported that SIM may be due to the 
statin-caused reduction of CoQ10. The CoQ10 supplementa-
tion has been proposed for the treatment of SIM. A successful 
trial with CoQ10 supplementation was reported by Caso 
et al,85 who assessed in a double-blinded protocol the effect of 
CoQ10 (100 mg/d, n = 18) or vitamin E (400 IU/d, n = 14) for 
30 days in patients with myopathic symptoms. Pain severity 
decreased by 40% (P , 0.001) and pain interference with 
daily activities decreased by 38% (P , 0.02) in the group 
treated with CoQ10. In contrast, no changes in pain sever-
ity (9%, P = not significant) or pain interference with daily 
activities (11%, P = not significant) were observed with 
vitamin E. These results suggest that CoQ10 supplementation 
may decrease muscle pain associated with statin treatment. 
However, these findings have not been replicated in larger 
trials and some concerns have been raised about the role of 
CoQ10 deficiency in the pathogenesis of SIM.18 Therefore, 
at present, the routine use of CoQ10 is not recommended in 
statin-intolerant patients.
It is well-known that vitamin deficiency is associated 
with myalgia and poor muscle function,86 which has led to 
the exploration of the potential benefits of vitamin supple-
mentation in SIM. In a recent trial, 38 patients with statin-
related myalgia and vitamin D levels below 32 ng/mL were 
treated with vitamin D supplementation.87 After completing 
3 months of vitamin D supplementation, the mean vitamin D 
levels increased and 92% of patients became myalgia free. 
This trial has several limitations, including its small study 
size and lack of a placebo group. These results, although 
interesting, need to be validated by a large randomized, 
double-blind, placebo-controlled trial.
In summary, even though these strategies have produced 
stimulating results, no specific recommendations can be 
issued concerning specific treatment to alleviate symptoms 
in patients presenting myalgia or myositis related to statin 
therapy.
Conclusion
In statin-intolerant patients the first step is to rule out any 
secondary causes of myopathy or liver toxicity (physical 
activity, hypothyroidism, drug interactions, related diseases). 
  Secondly, it is important to determine whether the adverse 
effects are indeed related to statin therapy by statin dechal-
lenge and rechallenge. If symptoms do not resolve, it is 
advisable to restart with the same statin at a lower   dosage or 
to switch to another statin. The selection of the new statins 
should favor molecules metabolized via different   pathways. In 
patients with a recurrence of symptoms, different approaches 
should be considered. Several small studies assessing uncon-
ventional dosing (every-other-day or weekly administra-
tion) of statins with longer half-life have been published. 
Although these studies presented encouraging alternatives 
for statin-intolerant patients, it has not been established 
that the cardiac risk reduction would be the same as with 
daily dosing regimens. Very few studies have evaluated the 
potential use of nonstatin lipid-lowering drugs (ezetimibe, 
bile acids sequestrants, and fibrates) alone or in combination 
in statin-intolerant patients. Therefore these approaches must 
be limited to selected patients after careful consideration of 
individual global cardiovascular and lipid targets. Finally, in 
low-risk individuals the use of herbal supplements effective 
in reducing LDL-C can be considered. At present, no specific 
recommendations can be issued regardig the use of these 
treatments for statin-induced myopathy.
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